Summary

The global postoperative pain management market size is likely to be valued at US$ 40 Bn in 2025 and is estimated to reach US$ 60.3 Bn by 2032, growing at a CAGR of 6.04% during the forecast period 2025-2032. The market growth is fueled by the increasing prevalence of surgical procedures, rising awareness regarding effective pain management solutions, and technological advancements in novel drug formulations and delivery systems.

Market Insights

Postoperative Pain Management Market - Report Scope:

The postoperative pain management market encompasses a wide range of pharmacological and non-pharmacological interventions aimed at reducing or eliminating pain after surgical procedures. With the growing surgical volume worldwide, particularly due to rising cases of cardiovascular, orthopedic, and bariatric surgeries, the demand for effective pain management therapies is increasing significantly. The availability of opioids, NSAIDs, local anesthetics, and multimodal analgesia has broadened the scope of treatment. Moreover, advancements in drug delivery systems such as transdermal patches and injectables are playing a pivotal role in improving patient compliance and outcomes.

Market Growth Drivers

Several factors are driving the growth of the global postoperative pain management market. The rising number of surgical interventions, coupled with growing awareness about the importance of effective pain relief in improving recovery, is a key growth determinant. Increasing adoption of minimally invasive procedures is also amplifying the need for pain management solutions that reduce postoperative discomfort. Moreover, advancements in multimodal analgesia, which minimizes opioid dependency, are further boosting market acceptance. The growing elderly population undergoing surgical treatments and increased healthcare spending worldwide are adding further momentum to market expansion.

Market Restraints

Despite positive growth trends, certain factors restrain the development of the postoperative pain management market. The ongoing opioid crisis and strict government regulations on opioid prescriptions have limited their widespread use, compelling healthcare providers to seek alternative solutions. High risks of drug dependency and side effects associated with long-term usage of pain-relieving drugs remain major concerns. Additionally, the lack of awareness in underdeveloped regions, coupled with limited access to advanced pain management therapies, poses a challenge to market penetration. Reimbursement limitations in several countries further restrict the affordability of advanced treatments.

Market Opportunities

The market presents substantial opportunities with the increasing focus on developing non-opioid analgesics and advanced multimodal therapies that ensure safe and effective pain management. The integration of patient-controlled analgesia (PCA) systems and personalized pain relief solutions holds strong growth potential. Emerging markets such as Asia-Pacific and Latin America, where healthcare infrastructure is rapidly improving, provide untapped avenues for market expansion. The growing trend of incorporating digital health technologies and AI-driven monitoring in pain management also opens new prospects. Collaborations between pharmaceutical companies and healthcare providers for research and development are expected to accelerate innovation in the sector.

Regional Outlook

North America leads the global postoperative pain management market, driven by advanced healthcare infrastructure, high surgical volumes, and the availability of innovative drug formulations. Europe follows closely, supported by favorable government initiatives to reduce opioid dependency and increasing adoption of multimodal therapies. The Asia-Pacific region is expected to witness the fastest growth during the forecast period, fueled by rising healthcare expenditure, increasing surgical procedures, and improving access to advanced treatments in countries such as China and India. Latin America and the Middle East & Africa are also emerging as promising markets due to government investments in healthcare modernization and a growing focus on patient-centered care.

Leading Companies

Key players in the global postoperative pain management market are actively focusing on innovation, partnerships, and regional expansion to strengthen their market presence. These include:

• Teva Pharmaceutical Industries Ltd

• Novartis AG

• Allergan plc

• GlaxoSmithKline plc

• Mylan N.V.

• Johnson & Johnson

• Pfizer Inc.

• Purdue Pharma L.P.

• Janssen Pharmaceuticals, Inc

• Endo International plc

• Baxter International

• Pacira Pharmaceuticals Inc.

• Cadila Healthcare Limited

• Cipla Limited

• Eisai Co., Ltd.

• LG Chem

• AbbVie Inc.

• Amgen Inc.

• Sun Pharmaceutical Ltd.

Market Segmentation

By Drug

• Opioids

o Tramadol

o Oxycodone

o Hydrocodone

o Other Opioids

• NSAIDs

• Local Anesthetics

• Acetaminophen

By Route of Administration

• Injectable

• Oral

• Rectal

• Topical

• Transdermal

• Others

By Prescription Type

• Over-the-counter (OTC) Products

• Prescription Drugs

By Distribution Channel

• Hospital Pharmacies

• Specialty Clinics

• Long Term Care Centers

• Retail Pharmacies

• Drug Stores

• Online Pharmacies

By Region

• North America

• Latin America

• Europe

• Asia Pacific

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Postoperative Pain Management Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Postoperative Pain Management Market Outlook, 2019-2032
3.1. Global Postoperative Pain Management Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Opioids
3.1.1.2. NSAIDs
3.1.1.3. Local Anesthetic
3.1.1.4. Acetaminophen
3.2. Global Postoperative Pain Management Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Injectable Postoperative Pain Management
3.2.1.2. Oral Postoperative Pain Management
3.2.1.3. Topical Postoperative Pain Management
3.2.1.4. Transdermal Postoperative Pain Management
3.2.1.5. Others
3.3. Global Postoperative Pain Management Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Drug Stores
3.3.1.4. Clinics
3.3.1.5. Others
3.4. Global Postoperative Pain Management Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Postoperative Pain Management Market Outlook, 2019-2032
4.1. North America Postoperative Pain Management Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Opioids
4.1.1.2. NSAIDs
4.1.1.3. Local Anesthetic
4.1.1.4. Acetaminophen
4.2. North America Postoperative Pain Management Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Injectable Postoperative Pain Management
4.2.1.2. Oral Postoperative Pain Management
4.2.1.3. Topical Postoperative Pain Management
4.2.1.4. Transdermal Postoperative Pain Management
4.2.1.5. Others
4.3. North America Postoperative Pain Management Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Drug Stores
4.3.1.4. Clinics
4.3.1.5. Others
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Postoperative Pain Management Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. U.S. Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
4.4.1.2. U.S. Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
4.4.1.3. U.S. Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.1.4. Canada Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
4.4.1.5. Canada Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
4.4.1.6. Canada Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Postoperative Pain Management Market Outlook, 2019-2032
5.1. Europe Postoperative Pain Management Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Opioids
5.1.1.2. NSAIDs
5.1.1.3. Local Anesthetic
5.1.1.4. Acetaminophen
5.2. Europe Postoperative Pain Management Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Injectable Postoperative Pain Management
5.2.1.2. Oral Postoperative Pain Management
5.2.1.3. Topical Postoperative Pain Management
5.2.1.4. Transdermal Postoperative Pain Management
5.2.1.5. Others
5.3. Europe Postoperative Pain Management Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Drug Stores
5.3.1.4. Clinics
5.3.1.5. Others
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Postoperative Pain Management Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Germany Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
5.4.1.2. Germany Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.3. Germany Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.4. U.K. Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
5.4.1.5. U.K. Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.6. U.K. Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.7. France Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
5.4.1.8. France Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.9. France Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.10. Italy Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
5.4.1.11. Italy Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.12. Italy Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.13. Turkey Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
5.4.1.14. Turkey Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.15. Turkey Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.16. Russia Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
5.4.1.17. Russia Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.18. Russia Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.19. Rest of Europe Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
5.4.1.20. Rest of Europe Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.21. Rest of Europe Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Postoperative Pain Management Market Outlook, 2019-2032
6.1. Asia Pacific Postoperative Pain Management Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Opioids
6.1.1.2. NSAIDs
6.1.1.3. Local Anesthetic
6.1.1.4. Acetaminophen
6.2. Asia Pacific Postoperative Pain Management Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Injectable Postoperative Pain Management
6.2.1.2. Oral Postoperative Pain Management
6.2.1.3. Topical Postoperative Pain Management
6.2.1.4. Transdermal Postoperative Pain Management
6.2.1.5. Others
6.3. Asia Pacific Postoperative Pain Management Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Drug Stores
6.3.1.4. Clinics
6.3.1.5. Others
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Postoperative Pain Management Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. China Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
6.4.1.2. China Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.3. China Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.4. Japan Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
6.4.1.5. Japan Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.6. Japan Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.7. South Korea Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
6.4.1.8. South Korea Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.9. South Korea Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.10. India Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
6.4.1.11. India Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.12. India Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.13. Southeast Asia Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
6.4.1.14. Southeast Asia Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.15. Southeast Asia Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.16. Rest of Asia Pacific Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
6.4.1.17. Rest of Asia Pacific Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.18. Rest of Asia Pacific Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Postoperative Pain Management Market Outlook, 2019-2032
7.1. Latin America Postoperative Pain Management Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Opioids
7.1.1.2. NSAIDs
7.1.1.3. Local Anesthetic
7.1.1.4. Acetaminophen
7.2. Latin America Postoperative Pain Management Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Injectable Postoperative Pain Management
7.2.1.2. Oral Postoperative Pain Management
7.2.1.3. Topical Postoperative Pain Management
7.2.1.4. Transdermal Postoperative Pain Management
7.2.1.5. Others
7.3. Latin America Postoperative Pain Management Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Drug Stores
7.3.1.4. Clinics
7.3.1.5. Others
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Postoperative Pain Management Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Brazil Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
7.4.1.2. Brazil Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
7.4.1.3. Brazil Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.4. Mexico Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
7.4.1.5. Mexico Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
7.4.1.6. Mexico Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.7. Argentina Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
7.4.1.8. Argentina Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
7.4.1.9. Argentina Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.10. Rest of Latin America Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
7.4.1.11. Rest of Latin America Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
7.4.1.12. Rest of Latin America Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Postoperative Pain Management Market Outlook, 2019-2032
8.1. Middle East & Africa Postoperative Pain Management Market Outlook, by Drug Class, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Opioids
8.1.1.2. NSAIDs
8.1.1.3. Local Anesthetic
8.1.1.4. Acetaminophen
8.2. Middle East & Africa Postoperative Pain Management Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Injectable Postoperative Pain Management
8.2.1.2. Oral Postoperative Pain Management
8.2.1.3. Topical Postoperative Pain Management
8.2.1.4. Transdermal Postoperative Pain Management
8.2.1.5. Others
8.3. Middle East & Africa Postoperative Pain Management Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Drug Stores
8.3.1.4. Clinics
8.3.1.5. Others
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Postoperative Pain Management Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. GCC Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
8.4.1.2. GCC Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.3. GCC Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.4. South Africa Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
8.4.1.5. South Africa Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.6. South Africa Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.7. Egypt Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
8.4.1.8. Egypt Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.9. Egypt Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.10. Nigeria Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
8.4.1.11. Nigeria Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.12. Nigeria Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.13. Rest of Middle East & Africa Postoperative Pain Management Market by Drug Class, Value (US$ Bn), 2019-2032
8.4.1.14. Rest of Middle East & Africa Postoperative Pain Management Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.15. Rest of Middle East & Africa Postoperative Pain Management Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Drug Class vs Route of Administration Heatmap
9.2. Company Market Share Analysis, 2024
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Teva Pharmaceutical Industries Ltd.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Novartis AG
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Allergan plc
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Mylan N.V.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Pfizer Inc.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Purdue Pharma L.P
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Janssen Pharmaceuticals, Inc.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Endo International plc.
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Pacira Pharmaceuticals Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Egalet Corporation
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. GlaxoSmithKline Plc.
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations